多索茶碱联合布地奈德对肥胖哮喘患者气道炎症及病情控制水平的影响
|
摘要
目的探究肥胖哮喘患者采用多索茶碱联合布地奈德的治疗方式对气道炎症及病情控制程度的影响。方法方便选取该院于2015年3月—2018年4月收治的肥胖且伴有哮喘的患者50例,以随机分组的方式,分为实验组(n=25,运用多索茶碱联合布地奈德的治疗方案)和对照组(n=25,应用氨茶碱的治疗方案),研究并分析两组患者在治疗前后炎症因子(TNF-α、IL-6)的表达水平、1 s用力呼气容积(FEV1)/用力肺活量(FVC)以及最大呼气流量(PEF)的变化程度。结果两组患者治疗后的炎症因子(TNF-α、IL-6)表达水平较治疗前均有所降低,且实验组中TNF-α=(21.21±4.24)μg/L、IL-6=(18.72±4.13)μg/L均显著低于对照组TNF-α=(29.68±4.45)μg/L、IL-6=(25.32±3.42)μg/L,(t=6.89,P=0.000,t=6.15,P=0.000);而治疗后的FEV1/FVC值以及PEF值较治疗前均有所提高,且实验组FEV1/FVC=(76.68±6.62)%;PEF=(4.95±0.51)L/s显著高于对照组FEV1/FVC=(64.14±5.26)%;PEF=(3.12±0.45)L/s (t=7.42,P=0.000;t=13.45,P=0.000),以上各项数据差异均具有统计学意义(P<0.05)。结论对肥胖哮喘患者采用多索茶碱联合布地奈德的治疗方式可以有效地降低炎症因子(TNF-α、IL-6)的表达水平,同时提高FEV1/FVC值和PEF值。
Objective To investigate the effect of treatment with doxofylline combined with budesonide on airway inflammation and disease control in obese asthma patients. Methods The authors convenient selected 50 patients with obesity and asthma in our hospital from March 2015 to April 2018. They were randomly divided into experimental group(n=25, using doxofylline combined with budesonide treatment plan) and the control group(n=25, treatment with aminophylline), studied and analyzed the expression levels of inflammatory factors(TNF-α, IL-6) in the two groups before and after treatment, 1 second forced Gas volume(FEV1)/forced vital capacity(FVC) and the degree of change in maximum expiratory flow(PEF).Results The expression levels of inflammatory factors(TNF-α, IL-6) in the two groups were lower than those before treatment, and in the experimental group TNF-α=(21.21±4.24)μg/L, IL-6=(18.72±4.13)μg/L, significantly lower than the control group TNF-α =(29.68 ±4.45)μg/, IL-6=(25.32±3.42)μg/L(t=6.89,P=0.000; t=6.15,P=0.000); and the FEV1/FVC value after treatment and PEF values were higher than before treatment, and the experimental group FEV1/FVC =(76.68 ±6.62)%;PEF=(4.95±0.51)L/s was significantly higher than the control group FEV1/FVC=(64.14 ±5.26)%; PEF=(3.12 ±0.45)L/s(t=67.42,P=0.000; t=13.45,P=0.000), the difference of the above data was statistically significant(P<0.05). Conclusion Treatment of obese asthma patients with doxofylline combined with budesonide can effectively reduce the expression levels of inflammatory factors(TNF-α, IL-6) and increase the FEV1/FVC and PEF values.
Objective To investigate the effect of treatment with doxofylline combined with budesonide on airway inflammation and disease control in obese asthma patients. Methods The authors convenient selected 50 patients with obesity and asthma in our hospital from March 2015 to April 2018. They were randomly divided into experimental group(n=25, using doxofylline combined with budesonide treatment plan) and the control group(n=25, treatment with aminophylline), studied and analyzed the expression levels of inflammatory factors(TNF-α, IL-6) in the two groups before and after treatment, 1 second forced Gas volume(FEV1)/forced vital capacity(FVC) and the degree of change in maximum expiratory flow(PEF).Results The expression levels of inflammatory factors(TNF-α, IL-6) in the two groups were lower than those before treatment, and in the experimental group TNF-α=(21.21±4.24)μg/L, IL-6=(18.72±4.13)μg/L, significantly lower than the control group TNF-α =(29.68 ±4.45)μg/, IL-6=(25.32±3.42)μg/L(t=6.89,P=0.000; t=6.15,P=0.000); and the FEV1/FVC value after treatment and PEF values were higher than before treatment, and the experimental group FEV1/FVC =(76.68 ±6.62)%;PEF=(4.95±0.51)L/s was significantly higher than the control group FEV1/FVC=(64.14 ±5.26)%; PEF=(3.12 ±0.45)L/s(t=67.42,P=0.000; t=13.45,P=0.000), the difference of the above data was statistically significant(P<0.05). Conclusion Treatment of obese asthma patients with doxofylline combined with budesonide can effectively reduce the expression levels of inflammatory factors(TNF-α, IL-6) and increase the FEV1/FVC and PEF values.
引文
[1]郝伟迤.布地奈德/福莫特罗治疗咳嗽变异性哮喘的临床效果及对血清IL-4、TNF-α的影响[J].解放军医药杂志,2018,30(6):79-82.
[2]羊德厚,陈庆通,杨妙浪,等.布地奈德福莫特罗粉吸入剂对咳嗽变异性哮喘患者咳嗽积分、诱导痰炎性介质及肺功能的影响[J].河北医药,2018,40(4):577-580.
[3]范菱.多索茶碱联合吸入剂治疗支气管哮喘急性发作的临床研究[J].海南医学院学报,2018,24(5):581-584.
[4]辛月.多索茶碱联合异丙托溴铵雾化吸入治疗支气管哮喘急性发作疗效及对肺功能和Th1/Th2型细胞因子的影响[J].解放军医药杂志,2018,30(10):73-77.
[5]陈国萍,朱兴龙.呼出气一氧化氮水平在支气管哮喘患者诊疗中的应用价值分析[J].河北医药,2018,40(6):898-900,905.
[6]张建丽.硫酸特布他林雾化液和布地奈德混悬液联合多索茶碱治疗变异性哮喘患儿的临床研究[J].中国临床药理学杂志,2017,33(22):2215-2218.
[7]陈秀珍,崇蕾,林罗娜.Adipo/AMPK信号通路的下调参与肥胖型哮喘小鼠的发病[J].基础医学与临床,2016,36(3):380-385.
[8]孔璐丹,张维溪,李昌崇.巨噬细胞极化与肥胖型哮喘[J].国际呼吸杂志,2016,36(13):1016-1019.
[9]Liu,Junli,Lee,etc..Treatment of Obesity with Celastrol[J].Cell,2015,161(5):999-1011.
[10]李剑,苗姝,佟金平,等.N-乙酰半胱氨酸对肥胖哮喘患者气道炎症及病情控制水平的影响[J].中国医刊,2018,53(12):1343-1345.
[11]刘榴,崇蕾,李昌崇.脂肪因子与支气管哮喘相关性的研究进展[J].国际呼吸杂志,2015,35(3):206-209.
[12]余红,杨惠英,刘银梅.孟鲁司特钠联合糖皮质激素治疗儿童支气管哮喘的疗效观察[J].山西医药杂志,2016,45(17):2025-2026.
[13]Inamdar,A.C.,Inamdar,etc.Mesenchymal stem cell therapy in lung disorders:Pathogenesis of lung diseases and mechanism of action of mesenchymal stem cell[J].Experimental lung research,2013,39(8):315-27.
[2]羊德厚,陈庆通,杨妙浪,等.布地奈德福莫特罗粉吸入剂对咳嗽变异性哮喘患者咳嗽积分、诱导痰炎性介质及肺功能的影响[J].河北医药,2018,40(4):577-580.
[3]范菱.多索茶碱联合吸入剂治疗支气管哮喘急性发作的临床研究[J].海南医学院学报,2018,24(5):581-584.
[4]辛月.多索茶碱联合异丙托溴铵雾化吸入治疗支气管哮喘急性发作疗效及对肺功能和Th1/Th2型细胞因子的影响[J].解放军医药杂志,2018,30(10):73-77.
[5]陈国萍,朱兴龙.呼出气一氧化氮水平在支气管哮喘患者诊疗中的应用价值分析[J].河北医药,2018,40(6):898-900,905.
[6]张建丽.硫酸特布他林雾化液和布地奈德混悬液联合多索茶碱治疗变异性哮喘患儿的临床研究[J].中国临床药理学杂志,2017,33(22):2215-2218.
[7]陈秀珍,崇蕾,林罗娜.Adipo/AMPK信号通路的下调参与肥胖型哮喘小鼠的发病[J].基础医学与临床,2016,36(3):380-385.
[8]孔璐丹,张维溪,李昌崇.巨噬细胞极化与肥胖型哮喘[J].国际呼吸杂志,2016,36(13):1016-1019.
[9]Liu,Junli,Lee,etc..Treatment of Obesity with Celastrol[J].Cell,2015,161(5):999-1011.
[10]李剑,苗姝,佟金平,等.N-乙酰半胱氨酸对肥胖哮喘患者气道炎症及病情控制水平的影响[J].中国医刊,2018,53(12):1343-1345.
[11]刘榴,崇蕾,李昌崇.脂肪因子与支气管哮喘相关性的研究进展[J].国际呼吸杂志,2015,35(3):206-209.
[12]余红,杨惠英,刘银梅.孟鲁司特钠联合糖皮质激素治疗儿童支气管哮喘的疗效观察[J].山西医药杂志,2016,45(17):2025-2026.
[13]Inamdar,A.C.,Inamdar,etc.Mesenchymal stem cell therapy in lung disorders:Pathogenesis of lung diseases and mechanism of action of mesenchymal stem cell[J].Experimental lung research,2013,39(8):315-27.